Orgenesis Inc (NASDAQ:ORGS) (FRA:45O) announced Monday it has signed a collaboration agreement with Dong-a University Hospital in South Korea and Cure Therapeutics Inc to utilize Orgenesis Mobile Processing Units and Labs (OMPULs).
The company said the teams will align to use the OMPULs for point-of-care development of cell and gene therapies and immunotherapies that meet regulatory and governmental approval standards to scale through to commercialization.
OMPULs are multi-purpose mobile autonomous good manufacturing practice (GMP) facilities intended to develop, optimize, and manufacture cell and gene therapies at the point of use.
READ: Orgenesis sees 3Q revenue rise by 40%, driven by rapid progress in its point-of-care network
Orgenesis said that process development and validation for the therapies will be completed at Dong-a University, leveraging the technologies in the Orgenesis POCare Platform to automate the processes for quality and reproducibility.
The company noted that the latest collaboration follows a recent joint venture agreement between Orgenesis and Cure Therapeutics, a developer of immuno-oncology and cell and gene therapies, to target cancer and infectious diseases.
Under the JV, Orgenesis said that both companies have agreed to collaborate in developing and commercializing Cure Therapeutics’ pipeline on a global basis, as well as developing, commercializing, and supplying Orgenesis’ therapeutic pipeline in South Korea and Japan.
“The OMPULs will be placed onsite with the goal of accelerating development and commercialization of our immunotherapies targeting cancers and infectious disease, while ensuring the highest quality control standards and reducing overall manufacturing costs,” said David Kim, CEO of Cure Therapeutics.
Vered Caplan, CEO of Orgenesis, added: “We are pleased to partner with Cure Therapeutics and Dong-a University Hospital to accelerate the development and market launch of breakthrough cell and gene therapies utilizing our proprietary OMPUL system. This latest agreement is another step in our efforts to rollout OMPULs throughout our network of leading healthcare facilities and partner companies across the U.S., Europe, Asia, and the Middle East.”
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham